文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

经导管三尖瓣置换术后生活质量:TRISCEND II关键试验1年结果

Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial.
PubMed 文献 · J Am Coll Cardiol · 2024-10-30

TRISCEND II关键试验随机分配400例有症状的重度及以上三尖瓣反流患者,2:1接受TTVR+OMT或单纯OMT。分析队列392例,TTVR+OMT组在30天、6个月和1年时KCCQ-OS较OMT组显著改善,组间差异分别为11.8、20.8和17.8分,1年时64.6%患者存活且状态良好。

要点

  • TTVR+OMT在30天即显现生活质量获益,6个月时改善幅度最大,并持续至1年。
  • 1年时TTVR+OMT组64.6%患者存活且KCCQ-OS≥60分且较基线下降<10分,OMT组为31.0%。
  • 极重度或大量三尖瓣反流患者较重度患者从TTVR+OMT中获益更大(交互P=0.049)。

核心结论

  • 对于有症状的重度及以上三尖瓣反流患者,与单纯OMT相比,TTVR+OMT可显著改善症状、功能和生活质量,获益在30天即出现,6个月持续增加,并维持至1年。

研究设计与样本

  • TRISCEND II关键试验将400例有症状的重度及以上三尖瓣反流患者按2:1随机分配至TTVR(EVOQUE系统)+OMT或单纯OMT。
  • 分析队列392例,其中259例尝试TTVR,133例接受单纯OMT;平均年龄79.2±7.6岁,75.5%为女性,56.1%为极重度或大量三尖瓣反流。
  • 采用堪萨斯城心肌病问卷(KCCQ)和36项简短健康调查(SF-36)评估健康状态,使用混合效应重复测量模型比较1年内变化。

主要发现

  • 基线健康状态显著受损:平均KCCQ总体摘要评分(KCCQ-OS)52.1±22.8,SF-36躯体健康成分摘要评分35.2±8.4。
  • TTVR+OMT组在30天、6个月和1年时KCCQ-OS组间差异分别为11.8分(95%CI:7.4-16.3)、20.8分(95%CI:16.1-25.5)和17.8分(95%CI:13.0-22.5),均有利于TTVR+OMT。
  • 亚组分析显示,极重度或大量三尖瓣反流患者较重度患者健康状态改善更大(治疗效果23.3 vs 22.6 vs 11.3;交互P=0.049)。
  • 1年时TTVR+OMT组64.6%患者存活且状态良好(KCCQ-OS≥60分且较基线下降<10分),单纯OMT组为31.0%。

临床怎么用

  • 对于有症状的重度及以上三尖瓣反流患者,TTVR+OMT可考虑用于改善症状、功能和生活质量,尤其适用于极重度或大量反流患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe tricuspid regurgitation (TR) often causes substantial impairment in patient-reported health status (ie, symptoms, physical and social function, and quality of life), which may improve with transcatheter tricuspid valve replacement (TTVR). OBJECTIVES: The authors performed an in-depth analysis of health status of patients enrolled in the TRISCEND (Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device) II pivotal trial to help quantify the benefit of intervention to patients. METHODS: The TRISCEND II pivotal trial randomized 400 patients with symptomatic and severe or greater TR 2:1 to TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT) or OMT alone. Health status was assessed with the Kansas City Cardiomyopathy Questionnaire and the 36-Item Short Form Health Survey. Changes in health status over 1 year were compared between treatment groups using mixed-effects repeated-measures models. RESULTS: The analysis cohort included 392 patients, of whom 259 underwent attempted TTVR and 133 received OMT alone (mean age 79.2 ± 7.6 years, 75.5% women, 56.1% with massive or torrential TR). Patients had substantially impaired health status at baseline (mean Kansas City Cardiomyopathy Questionnaire Overall Summary Score [KCCQ-OS] 52.1 ± 22.8; mean 36-Item Short Form Health Survey physical component summary score 35.2 ± 8.4). TTVR+OMT patients reported significantly greater improvement in both disease-specific and generic health status at each follow-up time point. Mean between-group differences in the KCCQ-OS favored TTVR+OMT at each time point: 11.8 points (95% CI: 7.4-16.3 points) at 30 days, 20.8 points (95% CI: 16.1-25.5 points) at 6 months, and 17.8 points (95% CI: 13.0-22.5 points) at 1 year. In subgroup analyses, TTVR+OMT improved health status to a greater extent among patients with torrential or massive TR vs severe TR (treatment effect 23.3 vs 22.6 vs 11.3; interaction P = 0.049). At 1 year, 64.6% of TTVR+OMT patients were alive and well (KCCQ-OS ≥60 points and no decline of ≥10 points from baseline) compared with 31.0% with OMT alone. CONCLUSIONS: Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients' symptoms, function, and quality of life. These benefits were evident 30 days after TTVR, continued to increase through 6 months, and remained durable through 1 year. (TRISCEND II Pivotal Trial [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device]; NCT04482062).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Arnold SV, Hahn RT, Thourani VH, et al. Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial. J Am Coll Cardiol. 2024. PMID: 39480380. doi:10.1016/j.jacc.2024.10.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。